CRSwNP endotype markers with nasal polyposis indicate the desirability of using biological medicines targeting these receptors (IgE, IL-4, IL-5, and IL-13), especially in the treatment of CRS with nasal polyps and asthma (IL-5). This evidence concerns the gene IL4 and chronic rhinosinusitis with nasal polyps.